The prognostic impact of FIt3/ITDs in relation to the fraction of CD34+ cells expressing CXCR-4
. | Relapse-free survival; n = 62 . | . | |
|---|---|---|---|
| Variable . | Relative risk (95% CI) . | P . | |
| CXCR-4 expression of 20% or more within the CD34+ subset | 13.4 (3.87-25.0) | < .001 | |
| Presence FIt3/ITDs | 1.54 (0.67-3.54) | .327 | |
| Unfavorable cytogenetic abnormalities* | 1.50 (0.81-2.63) | .048 | |
| Age | 0.57 (0.27-2.61) | .370 | |
. | Relapse-free survival; n = 62 . | . | |
|---|---|---|---|
| Variable . | Relative risk (95% CI) . | P . | |
| CXCR-4 expression of 20% or more within the CD34+ subset | 13.4 (3.87-25.0) | < .001 | |
| Presence FIt3/ITDs | 1.54 (0.67-3.54) | .327 | |
| Unfavorable cytogenetic abnormalities* | 1.50 (0.81-2.63) | .048 | |
| Age | 0.57 (0.27-2.61) | .370 | |
We performed a multivariate Cox regression analysis with fraction of CD34+ cells expressing CXCR-4, the presence FIt3- mutations, cytogenetics, and age as variables in the regression analysis. Results are presented as relative risks with 95% confidence intervals and respective P values. n = the number of samples included in the analysis.
See legend to Table 1.